有效结核治疗中痰转阴动态:系统综述与荟萃分析
该系统综述与荟萃分析受世界卫生组织委托,纳入44项研究,评估药物敏感肺结核有效治疗期间痰菌转阴动态。汇总估计显示治疗2周时涂片转阴仅9%,培养转阴率低,2个月时涂片转阴82%、固体培养转阴88%,液体培养转阴59%。多数患者在治疗2周时培养仍阳性,挑战了此间期后不具传染性的观点。
要点
- 治疗2周时涂片转阴仅9%,培养转阴率低,多数患者仍培养阳性。
- 治疗2个月时涂片转阴82%,固体培养转阴88%,液体培养转阴59%。
- 培养阳性仅为传染性一个组分,咳嗽频率和飞沫生成减少也重要。
核心结论
- 多数患者在结核治疗2周时培养仍阳性,挑战治疗后即不传染的观点。
- 培养阳性仅是传染性一个组分,需结合咳嗽动态综合评估传播风险。
研究设计与样本
- 世界卫生组织委托的系统综述与荟萃分析,检索MEDLINE、Embase等数据库。
- 纳入44项研究,其中27项为随机对照试验,17项为队列研究。
- 纳入接受有效治疗、培养确诊药物敏感肺结核的患者,任何设计且样本量≥10。
主要发现
- 治疗2周时涂片转阴9%(95%CI 3%-24%,1项研究,N=1)。
- 治疗2个月时涂片转阴82%(95%CI 78%-86%,N=10)。
- 基线涂片阳性患者中,2周时固体培养转阴5%(95%CI 0%-14%,N=2),2个月时88%(95%CI 84%-92%,N=20)。
- 液体培养在2周和2个月转阴分别为3%(95%CI 1%-16%,N=1)和59%(95%CI 47%-70%,N=8)。
- 观察到显著异质性,因缺乏HIV状态、基线涂片状态和空洞等分层数据而受限。
临床怎么用
- 应重新评估结核治疗2周后即不具传染性的假设,尤其对培养仍阳性患者。
- 结合咳嗽频率和飞沫生成等动态评估传染性,而非仅依赖培养转阴。
局限性
- 部分时间点数据仅来自单一研究,样本量有限。
- 显著异质性因缺乏HIV状态、基线涂片状态和空洞等分层数据而无法充分探讨。
- 未整合咳嗽动态、结核菌素皮肤试验转阳或早期杀菌活性等其他传染性证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Two weeks' isolation is widely recommended for people commencing treatment for pulmonary tuberculosis (TB). The evidence that this corresponds to clearance of potentially infectious tuberculous mycobacteria in sputum is not well established. This World Health Organization-commissioned review investigated sputum sterilisation dynamics during TB treatment. METHODS AND FINDINGS: For the main analysis, 2 systematic literature searches of OvidSP MEDLINE, Embase, and Global Health, and EBSCO CINAHL Plus were conducted to identify studies with data on TB infectiousness (all studies to search date, 1 December 2017) and all randomised controlled trials (RCTs) for drug-susceptible TB (from 1 January 1990 to search date, 20 February 2018). Included articles reported on patients receiving effective treatment for culture-confirmed drug-susceptible pulmonary TB. The outcome of interest was sputum bacteriological conversion: the proportion of patients having converted by a defined time point or a summary measure of time to conversion, assessed by smear or culture. Any study design with 10 or more particpants was considered. Record sifting and data extraction were performed in duplicate. Random effects meta-analyses were performed. A narrative summary additionally describes the results of a systematic search for data evaluating infectiousness from humans to experimental animals (PubMed, all studies to 27 March 2018). Other evidence on duration of infectiousness-including studies reporting on cough dynamics, human tuberculin skin test conversion, or early bactericidal activity of TB treatments-was outside the scope of this review. The literature search was repeated on 22 November 2020, at the request of the editors, to identify studies published after the previous censor date. Four small studies reporting 3 different outcome measures were identified, which included no data that would alter the findings of the review; they are not included in the meta-analyses. Of 5,290 identified records, 44 were included. Twenty-seven (61%) were RCTs and 17 (39%) were cohort studies. Thirteen studies (30%) reported data from Africa, 12 (27%) from Asia, 6 (14%) from South America, 5 (11%) from North America, and 4 (9%) from Europe. Four studies reported data from multiple continents. Summary estimates suggested smear conversion in 9% of patients at 2 weeks (95% CI 3%-24%, 1 single study [N = 1]), and 82% of patients at 2 months of treatment (95% CI 78%-86%, N = 10). Among baseline smear-positive patients, solid culture conversion occurred by 2 weeks in 5% (95% CI 0%-14%, N = 2), increasing to 88% at 2 months (95% CI 84%-92%, N = 20). At equivalent time points, liquid culture conversion was achieved in 3% (95% CI 1%-16%, N = 1) and 59% (95% CI 47%-70%, N = 8). Significant heterogeneity was observed. Further interrogation of the data to explain this heterogeneity was limited by the lack of disaggregation of results, including by factors such as HIV status, baseline smear status, and the presence or absence of lung cavitation. CONCLUSIONS: This systematic review found that most patients remained culture positive at 2 weeks of TB treatment, challenging the view that individuals are not infectious after this interval. Culture positivity is, however, only 1 component of infectiousness, with reduced cough frequency and aerosol generation after TB treatment initiation likely to also be important. Studies that integrate our findings with data on cough dynamics could provide a more complete perspective on potential transmission of Mycobacterium tuberculosis by individuals on treatment. TRIAL REGISTRATION: Systematic review registration: PROSPERO 85226.
引用
- Calderwood CJ, Wilson JP, Fielding KL, et al. Dynamics of sputum conversion during effective tuberculosis treatment: A systematic review and meta-analysis. PLoS Med. 2021. PMID: 33901173. doi:10.1371/journal.pmed.1003566
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。